← Metformin × all-cause mortality

Observational studyMedicine2016

Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study.

Young-Seok Seo et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 5,494 people · 2016

Randomised comparison

Reduced deaths

−62%−70% to −51%

Bigger than almost all for all-cause mortality

As reported

HR 0.38, 95% CI 0.30–0.49 · the paper's word: All-cause mortality

Randomised comparison

Reduced deaths

−59%−67% to −48%

Bigger than 9 in 10 for all-cause mortality

As reported

HR 0.41, 95% CI 0.33–0.52 · the paper's word: All-cause mortality

Randomised comparison

Reduced deaths

−60%−68% to −49%

Bigger than 9 in 10 for all-cause mortality

As reported

HR 0.40, 95% CI 0.32–0.51 · the paper's word: All-cause mortality

Not counted

Reduced deaths

−43%−59% to −22%

Bigger than 9 in 10 for all-cause mortality

As reported

HR 0.57, 95% CI 0.41–0.78 · the paper's word: All-cause mortality

Four numbers in the abstract

the abstract, start to end

… lower risk of HCC-specific mortality (HR 0.38, 95% confidence interval [CI] 0.30-0.49) and retreatment events (HR 0.41, 95% CI 0.33-0.52) compared …

… metformin nonusers (hazard ratio [HR] 0.40, 95% confidence interval [CI] …

… with those having an MPR of <80% (HR 0.57, 95% CI 0.41-0.78).

← favours treatmentfavours comparator →
could be chance
All-cause mortality
HR 0.380.30–0.49
All-cause mortality
HR 0.410.33–0.52
All-cause mortality
HR 0.400.32–0.51
All-cause mortality
HR 0.570.41–0.78
MetforminAll-cause mortality

Metformin × all-cause mortalityhelps?no deciding trial

unlikelylikely
0.25not counted
1 / 5

23 papers cite it

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 27124061